Though there are four histone deacetylase (HDAC) inhibitors that are FDA approved to treat some forms of lymphoma, there’s less evidence for their efficacy in solid tumors. Now, new findings in mice ...
Cereno Scientific’s hypertension drug was shown to improve the risk score of 43% of patients in a phase 2 study. Of the 21 participants with pulmonary arterial hypertension (PAH), nine demonstrated an ...
The HDAC inhibitor pipeline remains active, with several next-generation agents advancing in clinical trials. Abexinostat (Xynomic Pharmaceuticals) is in Phase III development for renal cell carcinoma ...
As gene regulation changes in Alzheimer’s disease, scientists believe that histone deacetylases (HDACs) go into overdrive, shutting down transcription of certain genes. Consequently, several research ...
DelveInsight’s 'HDAC Inhibitor Pipeline Insight 2023' report provides comprehensive global coverage of pipeline HDAC inhibitors in various stages of clinical development, major pharmaceutical ...
Most pancreatic tumors are surrounded by a thick, nearly impenetrable wall of fibrosis— scar tissue—that makes it hard for drugs to access and destroy the cancer cells. Researchers at the Salk ...
Chronic obstructive pulmonary disease (COPD) is characterized by chronic airway inflammation that is greater in patients with advanced disease. We asked whether there is a link between the severity of ...
Histone deacetylase (HDAC) antibodies are used to study the process of histone deacetylation, an essential activity that happens within human cells. Numerous assays currently exist that rely on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results